Mallotojaponins B and C: Total Synthesis, Antiparasitic Evaluation, and Preliminary SAR Studies

Tatyana D. Grayfer,[†] Philippe Grellier,[‡] Elisabeth Mouray,[‡] Robert H. Dodd,[†] Joëlle Dubois,*[,†] and Kevin Cariou*[,†]

[†]Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Sud, Univ. Paris-Saclay, 1, av. de la Terrasse, 91198 Gif-sur-Yvette, France

[‡]UMR 7245 CNRS, Département RDDM, Muséum National d'Histoire Naturelle CP52, 57 Rue Cuvier, 75005 Paris, France

S *Supporting Information*

ABSTRACT: The first total syntheses of mallotojaponin B and C as well as several analogues have been achieved. Biological evaluation of the synthesized compounds against *Plasmodium falciparum* and *Trypanosoma brucei* have also been carried out.

4 steps

protecting-group free

Mallotojaponin B (R = Me)
Mallotojaponin C (R = Prenyl)

Malaria is a tropical and subtropical disease caused by parasites of the *Plasmodium* genus carried by *Anopheles* mosquitoes, among which the most lethal form is caused by *Plasmodium falciparum*. Global estimations show that between 300 and 600 million people are infected and that about a million die every year from this infection. The discovery of new drugs for fighting this epidemic is essential, since resistances have emerged to most of the currently employed treatments. Natural products have constituted a seemingly endless source of inspiration for the development of drugs, as showcased by artemisinin, which is now the World Health Organization's recommended first-line treatment against malaria and for which discovery the Nobel Prize of Medicine was awarded in 2015. However, resistance to artemisinin has recently been reported and is spreading,[1] thus increasing the urgent need for developing alternative treatments. Mallotojaponins B (1) and C (2) are phloroglucinol dimers that have recently been isolated from a Madagascar euphorbiacea, *Mallotus oppositifolius*, that display potent antiplasmodial activities (Figure 1).[2]

In particular, mallotojaponin C displays both cytocidal and gametocidal activities (IC$_{50}$ = 0.14 μM and 3.6 μM, respectively) on *P. falciparum*, making it a good candidate for

further investigation. Following an ongoing interest in the development of novel antiparasitic compounds,[3] a program was initiated aimed at the synthesis of these two compounds and at the further evaluation of their biological activities. In particular, based on the difference of activity between mallotojaponins B and C, assessing the influence of the number of prenyl units was considered. Since the target compounds are dimeric, two strategies could be envisioned: functionalization followed by dimerization or vice versa. Based on our previous experience with the dimerization of phloroglucinol derivatives,[4] the latter route was initially deemed more convergent, especially toward homodimeric adducts. Thus, phloroacetophenone 3 was first treated with trimethylsilyldiazomethane[5] leading predominantly to the desired para-O-methylated product 4a (77% yield based on recovered starting material—brsm), along with minor amounts of o-O- and O,O'-dimethylated compounds 4b and 4c, respectively (Scheme 1).

The first set of mallotojaponin analogues was obtained by subjecting all three acetophenones 4a−c to methylation conditions using MOMCl (generated *in situ* from dimethoxymethane) followed by heating with hydrochloric acid (Scheme 2).[4] The corresponding bridged dimers 5a−c were all obtained


Figure 1. Mallotojaponins B and C: structure and activities against *P. falciparum* Dd2 (chloroquine/mefloquine-resistant strain).

Mallotojaponin B, **1** (R = Me)
(IC$_{50}$ = 0.75 μM; LD$_{50}$ = 6.7 μM)

Mallotojaponin C, **2** (R = Prenyl)
(IC$_{50}$ = 0.14 μM; LD$_{50}$ = 0.80 μM)

Scheme 1. Methylation of Phloroacetophenone 3

TMSCHN$_2$ (3 equiv)

CHCl$_3$/MeOH, 2:1

4a, R = Me, R' = H (43%)
4b, R = H, R' = Me (5%)
4c, R = R' = Me (6%)
3, R = R' = H (44%)

A

Scheme 2. Methylenation of Acetophenones 4a-c

4a, R = Me, R' = H   **5a**, R = Me, R' = H (90%)
4b, R = H, R' = Me   **5b**, R = H, R' = Me (86%)
4c, R = R' = Me   **5c**, R = R' = Me (82%)

with excellent yields; however, further elaboration of these substrates to mallotojaponins, especially C-prenylation, proved extremely laborious.[6]

At this stage, the strategy was reconsidered, and the functionalized monomers were targeted first before carrying out the dimerization, keeping in mind that the ideal protocol should grant access to both homo- and heterodimeric compounds. Although well documented,[7] selective C-prenylation of compound **4a** was found to be the major hurdle to overcome in this endeavor. Many multistep strategies such as selective TBS-monoprotection/O-prenylation[8] or selective O-prenylation followed by Claisen rearrangement and Pd-catalyzed O-3,3-dimethylallylation/sigmatropy[9] were evaluated to little or no avail. Finally, direct C-prenylation with prenyl bromide,[10] in the presence of Hünig's base in dichloromethane, offered the best compromise (Scheme 3).[11] Indeed, a

Scheme 3. Prenylation, Geranylation, and Methylation of Acetophenone 4a

4a

6, R = H (36%) (+ **4a**, 33%)
**7**, R = Prenyl (30%) (+ **4a**, 41%)

8

reasonable 53% (brsm) yield of prenylated phenol **6** could be attained, and these conditions also enabled the isolation of the corresponding geranyl adduct **7** (51% brsm). The synthesis of methylated monomer **8** has previously been reported by a three-step sequence starting with 2,4,6-trihydroxybenzalde-hyde.[12] Nevertheless, direct access from readily available **4a** was thought to be more practical. This was achieved by a two-step sequence involving formylation with dichloro(methoxy)-methane[13] followed by reduction using sodium cyanoborohy-dride under acidic conditions.[14]

With these three functionalized monomers in hand, the dimerization reaction was attempted, which was unsuccessful using the MOMCl protocol.[15] After various formaldehyde equivalents were screened, Eschenmoser's salt was eventually

considered, as it was briefly reported by Minassi and Appendino to be a suitable promoter for this kind of transformation in the synthesis of arzanol.[16] Reacting prenylated monomer **6** with 0.5 equiv of the methylene salt allowed the synthesis of mallotojaponin C (**2**) in 35% yield (Scheme 4). In order to improve the efficiency of this final step,

Scheme 4. Synthesis of Mallotojaponin C

the reagent-to-starting material ratio was increased. Interestingly, when 3 equiv of reagents was used, exclusive formation of the dimethylammonium salt took place, giving **9** in 95% yield. This platform could in turn be reacted with 1 equiv of the starting monomer **6** to give the desired natural product in quantitative yield.[17]

This encouraging result prompted us to synthesize the two remaining dimethylammonium salts **10** and **11** from the corresponding geranylated and methylated phenols **7** and **8**, respectively. This was achieved by reacting each monomer with the Eschenmoser's salt in chloroform at room temperature (Scheme 5).

Scheme 5. Synthesis of Dimethylammonium Salts 10 and 11

7, R = Geranyl   **10**, R = Geranyl (82%)
                             (n = 3.0 , t = 1.15 h)
8, R = Methyl   **11**, R = Methyl (quant)
                             (n = 1.0 , t = 1.15 h)

With both the phenols and the ammonium salts now available an efficient access to either homo- or heterodimers was within reach. First, digeranyl and dimethyl adducts **12** and **13** could indeed be obtained with excellent yields by reacting together the similarly substituted phenols and salts (Table 1, entries 1 and 2). The latter compound **13** is actually mallotophenone, another naturally occurring phloroglucinol dimer, that was also isolated from *Mallotus* species.[2,18] Heterodimers could in turn be obtained with good yields (Table 1, entries 3−5) by reacting together phenols and salts bearing different substituents such as geranyl/prenyl **14**,

Table 1. Synthesis of Dimers 12−15 and 1[a]

entry	R	R′	time (min)	dimer, yield (%)
1	**7**, geranyl	**10**, geranyl	90	**12**, 98
2	**8**, methyl	**11**, methyl	50	**13**, 94
3	**7**, geranyl	**9**, prenyl	75	**14**, 83
4	**8**, methyl	**10**, geranyl	60	**15**, 68
5	**8**, methyl	**9**, prenyl	45	**1**, 62

[a]Isolated yields.

geranyl/methyl **15** and prenyl/methyl (i.e., mallotojaponin B, **1**).

Following our initial objective, the antimalarial activity (Table 2, column 3) of the various synthesized compounds

Table 2. Evaluation of Antiparasitic and Enzyme Inhibitory Activities[a]

entry	compd	*P. falciparum*[b]	*T. brucei*[c]	farnesyl transferase[d]
1	**1**	3.4 ± 0.2	1.0 ± 1.0	>30
2	**2**	0.75 ± 0.11	0.45 ± 0.01	2.0 ± 0.3
3	**13**	12.9 ± 4.6	7.9 ± 0.4	>30
4	**5a**	17.6 ± 4.3	10 ± 1.1	25.5 ± 2.9
5	**5b**	>50	>50	>30
6	**5c**	>50	>50	>30
7	**12**	6.0 ± 0.4	3.7 ± 0.2	>30
8	**14**	2.1 ± 1.3	1.1 ± 0.04	14.4 ± 2.4
9	**15**	1.0 ± 0.8	0.53 ± 0.03	5.2 ± 0.5
10	**16**	2.0 ± 1.3	0.77 ± 0.08	4.4 ± 0.7
11	**17**	4.1 ± 0.9	2.0 ± 0.2	22.8 ± 6.9
12	**6**	7.4 ± 1.1	27 ± 0.8	>30
13	**7**	4.4 ± 1.3	8.5 ± 0.2	>30
14	**8**	>50	>50	>30
15	**9**	3.5 ± 0.5	4.1 ± 0.1	>30
16	**10**	3.7 ± 0.1	8.4 ± 0.6	>30

[a]IC$_{50}$ (μM). [b]Chloroquine-resistant *P. falciparum* FcB1/Colombia strain; chloroquine was used as antimalarial drug control (IC$_{50}$ = 0.072 ± 0.0074 μM). [c]*T. brucei brucei* strain 93; pentamidine was used as antitrypanosomal drug control (IC$_{50}$ = 0.011 ± 0.0017 μM). [d]*T. brucei brucei* protein farnesyl transferase; under these conditions, the commercially available inhibitor FTI-276 displayed an IC$_{50}$ = 0.010 ± 0.002 μM.

was first evaluated on the intraerythrocytic stage of *P. falciparum*, starting with natural products **1**, **2**, and **13** (Table 2, entries 1−3). While the measured IC$_{50}$'s are slightly higher than the ones reported[2] (on a different strain), the same order of potency prevails, with diprenylated mallotojaponin C (Table 2, entry 2) being the most active, followed by monoprenylated mallotojaponin B (Table 2, entry 1) and nonprenylated mallotophenone (Table 2, entry 3). Unsubstituted dimers with different methoxylation patterns **5a**−**c** (Table 2, entries

4−6) display at best modest activity against *P. falciparum*. Only **5a**, which structurally most resembles **13**, displays an activity below 50 μM (Table 2, entry 4). Micromolar activities were restored with geranyl-substituted dimers **12**, **14**, and **15** (Table 2, entries 7−9). The most active compound of this latter series is monogeranylated **15** (IC$_{50}$ = 1.0 μM) (Table 2, entry 9). In order to further probe the influence of the prenyl units, diisopentyl dimer **16** and diallyl dimer **17** were also synthesized and evaluated.[19] Both analogues were found to be more active (Table 2, entries 10 and 11) than mallotojaponin B (**1**), yet less so than mallotojaponin C (**2**), thus demonstrating the activating influence of the prenyl units. Finally, several monomers and salts were also tested for their anti-*plasmodium* activity (Table 2, entries 12−16). All monomers except methylated phenol **8** exhibited some inhibitory potency, with the most active of these (**7**, IC$_{50}$ = 4.4 μM) bearing a geranyl unit (Table 2, entry 13). Both dimethylammonium salts **9** and **10** were found to be active (Table 2, entries 15 and 16), although this could be mostly due to their intrinsic reactive nature. The scope of this study was further extended by screening all compounds against the bloodstream forms of *T. brucei*, the parasite responsible for trypanosomiasis in humans and cattle (Table 2, column 4). Interestingly, an activity profile that almost mirrors that found against *P. falciparum* could be evidenced with the three most active compounds (Table 2, entries 2, 9, and 10) also being mallotojaponin C (**2**), methyl/geranyl dimer **15**, and saturated dimer **16** (IC$_{50}$ = 0.45, 0.53, and 0.77 μM, respectively). Finally, considering the apparent importance of the prenyl units for activity, the substrates were also tested as potential inhibitors of *T. brucei* protein farnesyl transferase (Table 2, column 5). A moderate correlation could thus be observed as mallotojaponin C (**2**) and methyl/geranyl dimer **15** were found to be good inhibitors of the enzyme in the micromolar range (IC$_{50}$ = 2.0 and 5.2 μM, respectively). However, in this regard, saturated analogue **16** still appears as a relatively potent compound (IC$_{50}$ = 4.4 μM) (Table 2, entry 10).

Overall, these synthetic efforts culminated in the first total syntheses of three natural products that were recently isolated from *M. oppositifolius*: mallotojaponins B and C as well as mallotophenone.[2] Biological evaluation of these compounds and of various analogues confirmed their promising antimalarial activity and uncovered an interesting trypanocidal activity. Preliminary SAR studies showed the importance of the two prenyl units and of the dimeric structure. Further synthetic and biological studies are currently underway to explore the full therapeutic potential of this family of compounds and will be reported in due course.

■ ASSOCIATED CONTENT

Ⓢ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.5b03676.

Synthetic and biological protocols; copies of NMR spectra (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: joëlle.dubois@cnrs.fr.
*E-mail: kevin.cariou@cnrs.fr.

Notes

The authors declare no competing financial interest.

■ REFERENCES

(1) Ashley, E. A.; et al. *N. Engl. J. Med.* **2014**, *371*, 411.

(2) Harinantenaina, L.; Bowman, J. D.; Brodie, P. J.; Slebodnick, C.; Callmander, M. W.; Rakotobe, E.; Randrianaivo, R.; Rasamison, V. E.; Gorka, A.; Roepe, P. D.; Cassera, M. B.; Kingston, D. G. I. *J. Nat. Prod.* **2013**, *76*, 388.

(3) (a) Bosc, D.; Mouray, E.; Grellier, P.; Cojean, S.; Loiseau, P.; Dubois, J. *MedChemComm* **2013**, *4*, 1034. (b) Thévenin, M.; Thoret, S.; Grellier, P.; Dubois, J. *Bioorg. Med. Chem.* **2013**, *21*, 4885.

(4) Thévenin, M.; Mouray, E.; Grellier, P.; Dubois, J. *Eur. J. Org. Chem.* **2014**, *2014*, 2986.

(5) (a) Tsujihara, K.; Hongu, M.; Saito, K.; Kawanishi, H.; Kuriyama, K.; Matsumoto, M.; Oku, A.; Ueta, K.; Tsuda, M.; Saito, A. *J. Med. Chem.* **1999**, *42*, 5311. (b) Basabe, P.; de Román, M.; Marcos, I. S.; Diez, D.; Blanco, A.; Bodero, O.; Mollinedo, F.; Sierra, B. G.; Urones, J. G. *Eur. J. Med. Chem.* **2010**, *45*, 4258.

(6) Prenylation of **5a** did provide a minor amount of mallotojaponin C (ca. 15%) that was difficult to isolate and purify.

(7) For a review on this topic, see: Hoareau, C.; Pettus, T. R. R. *Synlett* **2003**, 127.

(8) Minassi, A.; Giana, A.; Ech-Chahad, A.; Appendino, G. *Org. Lett.* **2008**, *10*, 2267.

(9) (a) Tisdale, E. J.; Slobodov, I.; Theodorakis, E. A. *Org. Biomol. Chem.* **2003**, *1*, 4418. (b) Tisdale, E. J.; Slobodov, I.; Theodorakis, E. A. *Proc. Natl. Acad. Sci. U. S. A.* **2004**, *101*, 12030. (c) Batova, A.; Lam, T.; Wascholowski, V.; Yu, A. L.; Giannis, A.; Theodorakis, E. A. *Org. Biomol. Chem.* **2007**, *5*, 494. (d) Chantarasriwong, O.; Cho, W. C.; Batova, A.; Chavasiri, W.; Moore, C.; Rheingold, A. L.; Theodorakis, E. A. *Org. Biomol. Chem.* **2009**, *7*, 4886.

(10) (a) Lee, Y. R.; Li, X.; Kim, J. H. *J. Org. Chem.* **2008**, *73*, 4313. (b) Wang, X.; Lee, Y. R. *Tetrahedron* **2011**, *67*, 9179.

(11) Numerous combinations of base, solvent, and electrophiles were tested, including those used in refs 10a (Hünig's base in DMF for geranylation) and 10b (DBU in THF for prenylation).

(12) Nakagawa-Goto, K.; Lee, K.-H. *Tetrahedron Lett.* **2006**, *47*, 8263.

(13) Bergman, J.; Renstrom, L.; Sjoberg, B. *Tetrahedron* **1980**, *36*, 2505.

(14) Elliger, C. A. *Synth. Commun.* **1985**, *15*, 1315.

(15) When this protocol was used, the major isolated compound was the corresponding pyran arising from cyclization of the prenyl chain (see the Supporting Information for details). Acidic conditions are known to promote such cyclizations. For representative examples, see: (a) Sugamoto, K.; Matsusita, Y.; Matsui, K.; Kurogi, C.; Matsui, T. *Tetrahedron* **2011**, *67*, 5346. (b) Narender, K.; Reddy, K. P. *Tetrahedron Lett.* **2007**, *48*, 7628 and references therein.

(16) Minassi, A.; Cicione, L.; Koeberle, A.; Bauer, J.; Laufer, S.; Werz, O.; Appendino, G. *Eur. J. Org. Chem.* **2012**, *2012*, 772.

(17) In our hands, this two-step protocol was found to be quite robust and could be carried out to give more than 0.2 g of mallotojaponin C in one given sequence; see the Supporting Information for details. The same strategy has very recently been applied to the synthesis of rottlerin; see: Hong, K. K. C.; Ball, G. E.; Black, D. StC.; Kumar, N. *J. Org. Chem.* **2015**, *80*, 10668.

(18) Mallotophenone was first isolated from *Mallotus japonicus*; see: (a) Arisawa, M.; Fujita, A.; Suzuki, R.; Hayashi, T.; Morita, N.; Kawano, N.; Koshimura, S. *J. Nat. Prod.* **1985**, *48*, 455. However, the synthesis of this compound had been previously reported; see: (b) McGookin, A.; Robertson, A.; Simpson, T. H. *J. Chem. Soc.* **1951**, 2021.

(19) Diisopentyl compound **16** was obtained by hydrogenation on Pd/C of mallotojaponin C, and diallyl compound **17** was prepared in three steps from **4a**; see the Supporting Information for details.